Unknown

Dataset Information

0

Posttransplant peripheral blood donor-specific interferon-? enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.


ABSTRACT: Noninvasive diagnosis of kidney allograft inflammation in transplant recipients with stable graft function (subclinical rejection) could permit more effective therapy and prevent later development of de novo anti-donor HLA antibodies and/or graft dysfunction. Here we tested whether quantifying posttransplant donor-specific alloreactive T-cells by IFN-? ELISPOT assay noninvasively detects subclinical T-cell mediated rejection and/or predicts development of anti-donor HLA antibodies. Using an initial cross-sectional cohort of 60 kidney transplant patients with six-month surveillance biopsies, we found that negative donor-specific IFN-? ELISPOT assays accurately ruled out the presence of subclinical T-cell mediated rejection. These results were validated using a distinct prospective cohort of 101 patients where donor-specific IFN-? ELISPOT results at both three- and six-months posttransplant significantly differentiated patients with subclinical T-cell mediated rejection at six months, independent of other clinical variables (odds ratio 0.072, 95% confidence interval 0.008-0.653). The posttransplant donor-specific IFN-? ELISPOT results independently associated with subsequent development of significant anti-donor HLA antibodies (0.085, 0.008-0.862) and with significantly worse two-year function (estimated glomerular filtration rate) compared to patients with a negative test. Thus, posttransplant immune monitoring by donor-specific IFN-? ELISPOT can assess risk for developing subclinical T-cell mediated rejection and anti-donor HLA antibodies, potentially limiting the need for surveillance biopsies. Our study provides a guide for individualizing immunosuppression to improve posttransplant outcomes.

SUBMITTER: Crespo E 

PROVIDER: S-EPMC5930006 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

altmetric image

Publications

Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.

Crespo Elena E   Cravedi Paolo P   Martorell Jaume J   Luque Sergi S   Melilli Edoardo E   Cruzado Josep M JM   Jarque Marta M   Meneghini Maria M   Manonelles Anna A   Donadei Chiara C   Lloberas Núria N   Gomà Montse M   Grinyó Josep M JM   Heeger Peter P   Bestard Oriol O  

Kidney international 20170306 1


Noninvasive diagnosis of kidney allograft inflammation in transplant recipients with stable graft function (subclinical rejection) could permit more effective therapy and prevent later development of de novo anti-donor HLA antibodies and/or graft dysfunction. Here we tested whether quantifying posttransplant donor-specific alloreactive T-cells by IFN-γ ELISPOT assay noninvasively detects subclinical T-cell mediated rejection and/or predicts development of anti-donor HLA antibodies. Using an init  ...[more]

Similar Datasets

| S-EPMC6133406 | biostudies-literature
| S-EPMC8602732 | biostudies-literature
| S-EPMC9395307 | biostudies-literature
| S-EPMC5461792 | biostudies-literature
| S-EPMC8232017 | biostudies-literature
| S-EPMC6509825 | biostudies-literature
| S-EPMC6235372 | biostudies-literature
| S-EPMC6363903 | biostudies-literature
| S-EPMC6968335 | biostudies-literature
| S-EPMC8610940 | biostudies-literature